Similarly, another rationally designed BD2-selective BET inhibitor (SJ432) (Figure 5D) was recently shown to produce remarkable antitumor potency at a relatively low dose of 15 mg/kg in various neuroblastoma models without notable toxic effects in vivo [86]. The gene discussed is DNER; the disease is neuroblastoma.